Search

Corcept Therapeutics Inc

Open

SectorGezondheidszorg

123.37 0.77

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

121.51

Max

125.97

Belangrijke statistieken

By Trading Economics

Inkomsten

75M

43M

Verkoop

91M

256M

K/W

Sectorgemiddelde

254.717

57.371

EPS

0.36

Winstmarge

16.782

Werknemers

730

EBITDA

91M

47M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+14.41% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.9B

13B

Vorige openingsprijs

122.6

Vorige sluitingsprijs

123.37

Nieuwssentiment

By Acuity

59%

41%

292 / 340 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 19:36 UTC

News

Corcept Therapeutics shares are lower despite Zacks raising Q3 2026 EPS estimate to $0.34. The company reported Q2 earnings of $0.36 per share.

21 aug 2026, 20:01 UTC

News

Corcept Therapeutics Inc is higher today, supported by strong sector performance and increased trading volume amid a positive growth outlook and upcoming FDA decision on Relacorilant.

20 aug 2026, 23:41 UTC

Corcept Therapeutics Inc. shares are trading roughly flat in after-market hours. The asset remains above its 20-day moving average.

13 aug 2026, 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11 aug 2026, 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7 aug 2026, 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5 aug 2026, 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 aug 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 jul 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 jul 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 jul 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 jul 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 jul 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24 jul 2026, 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22 jul 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21 jul 2026, 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 jul 2026, 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

14.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 141 USD  14.41%

Hoogste 165 USD

Laagste 50 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Sentiment

By Acuity

292 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat